Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short–duration response and multifocal intracerebral recurrence preceding radiotherapy

D. H. Lachance, D. M. Brizel, J. P. Gockerman, E. C. Halperin, P. C. Burger, Orest Boyko, M. T. Brown, S. C. Schold

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients. Primary lesions were reduced by 80% or more on contrast–enhancing cross–sectional area in four patients and to a lesser extent in two others after two cycles of chemotherapy. The primary lesion sites demonstrated no contrast enhancement in the three patients who completed four cycles of therapy. However, concurrent with response at the primary disease sites, multiple lesions occurred at distant, noncontiguous CNS parenchymal sites in five patients after two to four cycles of chemotherapy. Median survival was 8.5 months for the six enrolled patients and 16.5 months for the four patients completing craniospinal radiotherapy. PCNSL is highly responsive to standard systemic non–Hodgkin's lymphoma chemotherapy regimens, but the pattern and rapidity of relapse suggest mechanisms of failure including inherent or rapidly evolving antineoplastic drug resistance and perhaps limited drug delivery to occult sites of disease in the brain.

Original languageEnglish (US)
Pages (from-to)1721-1727
Number of pages7
JournalNeurology
Volume44
Issue number9
StatePublished - 1994
Externally publishedYes

Fingerprint

Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Lymphoma
Radiotherapy
Central Nervous System
Recurrence
Drug Therapy
Neoplasm Drug Resistance
Brain Diseases
Non-Hodgkin's Lymphoma
Survival
Therapeutics
Pharmaceutical Preparations
Lesion
Chemotherapy

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Lachance, D. H., Brizel, D. M., Gockerman, J. P., Halperin, E. C., Burger, P. C., Boyko, O., ... Schold, S. C. (1994). Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short–duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology, 44(9), 1721-1727.

Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma : Short–duration response and multifocal intracerebral recurrence preceding radiotherapy. / Lachance, D. H.; Brizel, D. M.; Gockerman, J. P.; Halperin, E. C.; Burger, P. C.; Boyko, Orest; Brown, M. T.; Schold, S. C.

In: Neurology, Vol. 44, No. 9, 1994, p. 1721-1727.

Research output: Contribution to journalArticle

Lachance, DH, Brizel, DM, Gockerman, JP, Halperin, EC, Burger, PC, Boyko, O, Brown, MT & Schold, SC 1994, 'Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short–duration response and multifocal intracerebral recurrence preceding radiotherapy', Neurology, vol. 44, no. 9, pp. 1721-1727.
Lachance, D. H. ; Brizel, D. M. ; Gockerman, J. P. ; Halperin, E. C. ; Burger, P. C. ; Boyko, Orest ; Brown, M. T. ; Schold, S. C. / Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma : Short–duration response and multifocal intracerebral recurrence preceding radiotherapy. In: Neurology. 1994 ; Vol. 44, No. 9. pp. 1721-1727.
@article{4cd12f38acd44114be245d643e9755dd,
title = "Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short–duration response and multifocal intracerebral recurrence preceding radiotherapy",
abstract = "The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients. Primary lesions were reduced by 80{\%} or more on contrast–enhancing cross–sectional area in four patients and to a lesser extent in two others after two cycles of chemotherapy. The primary lesion sites demonstrated no contrast enhancement in the three patients who completed four cycles of therapy. However, concurrent with response at the primary disease sites, multiple lesions occurred at distant, noncontiguous CNS parenchymal sites in five patients after two to four cycles of chemotherapy. Median survival was 8.5 months for the six enrolled patients and 16.5 months for the four patients completing craniospinal radiotherapy. PCNSL is highly responsive to standard systemic non–Hodgkin's lymphoma chemotherapy regimens, but the pattern and rapidity of relapse suggest mechanisms of failure including inherent or rapidly evolving antineoplastic drug resistance and perhaps limited drug delivery to occult sites of disease in the brain.",
author = "Lachance, {D. H.} and Brizel, {D. M.} and Gockerman, {J. P.} and Halperin, {E. C.} and Burger, {P. C.} and Orest Boyko and Brown, {M. T.} and Schold, {S. C.}",
year = "1994",
language = "English (US)",
volume = "44",
pages = "1721--1727",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma

T2 - Short–duration response and multifocal intracerebral recurrence preceding radiotherapy

AU - Lachance, D. H.

AU - Brizel, D. M.

AU - Gockerman, J. P.

AU - Halperin, E. C.

AU - Burger, P. C.

AU - Boyko, Orest

AU - Brown, M. T.

AU - Schold, S. C.

PY - 1994

Y1 - 1994

N2 - The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients. Primary lesions were reduced by 80% or more on contrast–enhancing cross–sectional area in four patients and to a lesser extent in two others after two cycles of chemotherapy. The primary lesion sites demonstrated no contrast enhancement in the three patients who completed four cycles of therapy. However, concurrent with response at the primary disease sites, multiple lesions occurred at distant, noncontiguous CNS parenchymal sites in five patients after two to four cycles of chemotherapy. Median survival was 8.5 months for the six enrolled patients and 16.5 months for the four patients completing craniospinal radiotherapy. PCNSL is highly responsive to standard systemic non–Hodgkin's lymphoma chemotherapy regimens, but the pattern and rapidity of relapse suggest mechanisms of failure including inherent or rapidly evolving antineoplastic drug resistance and perhaps limited drug delivery to occult sites of disease in the brain.

AB - The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients. Primary lesions were reduced by 80% or more on contrast–enhancing cross–sectional area in four patients and to a lesser extent in two others after two cycles of chemotherapy. The primary lesion sites demonstrated no contrast enhancement in the three patients who completed four cycles of therapy. However, concurrent with response at the primary disease sites, multiple lesions occurred at distant, noncontiguous CNS parenchymal sites in five patients after two to four cycles of chemotherapy. Median survival was 8.5 months for the six enrolled patients and 16.5 months for the four patients completing craniospinal radiotherapy. PCNSL is highly responsive to standard systemic non–Hodgkin's lymphoma chemotherapy regimens, but the pattern and rapidity of relapse suggest mechanisms of failure including inherent or rapidly evolving antineoplastic drug resistance and perhaps limited drug delivery to occult sites of disease in the brain.

UR - http://www.scopus.com/inward/record.url?scp=0028136259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028136259&partnerID=8YFLogxK

M3 - Article

C2 - 7936304

AN - SCOPUS:0028136259

VL - 44

SP - 1721

EP - 1727

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -